Table 1.
Nine randomized controlled trials included in the meta-analysis
| Trial | Study design | Number | HR for OS | HR for PFS | HR for PSA | Jadad Score |
|---|---|---|---|---|---|---|
| Joel 2012 | zibotentan | 299 | 0.87 | 1.01 | N | 5 |
| phase III | placebo | 295 | ||||
| Karim 2013 | Docetaxel+zibotentan | 524 | 1.00 | 1.00 | N | 5 |
| phase III | Docetaxel+placebo | 528 | ||||
| Miller 2013 | zibotentan | 703 | 1.13 | 0.89 | N | 3 |
| phase III | placebo | 712 | ||||
| Nicholas 2010 | zibotentan | 107 | 0.83 | 1.06 | N | 3 |
| phase II | placebo | 107 | ||||
| Nicholas 2008 | zibotentan | 107 | 0.55 | 0.88 | N | 3 |
| phase II | placebo | 107 | ||||
| Michael 2007 | atrasentan | 408 | 0.97 | 0.89 | 0.86 | 4 |
| phase III | placebo | 401 | ||||
| David 2013 | Docetaxel+atrasentan | 498 | 1.04 | 1.02 | N | 4 |
| phase III | Docetaxel+placebo | 496 | ||||
| Joel 2008 | atrasentan | 467 | 0.92 | 0.92 | 0.92 | 4 |
| phase III | placebo | 474 | ||||
| Michael 2003 | atrasentan | 89 | N | 0.80 | 0.75 | 4 |
| phase II | placebo | 104 |